What is the Theragen Etex Co., Ltd. stock price forecast?

Theragen Etex Co., Ltd. is currently trading at ₩2,410. View real-time AI analysis on Alpha Lenz.

What is Theragen Etex Co., Ltd. insider trading activity?

View the latest insider trading data for Theragen Etex Co., Ltd. on Alpha Lenz.

What is Theragen Etex Co., Ltd.'s P/E ratio?

Theragen Etex Co., Ltd.'s P/E ratio is 8.4.

Theragen Etex Co., Ltd.

KRX · 066700

₩2,410+25(+1.05%)Market closed

Ask about Theragen Etex Co., Ltd.'s future dividend policy...

Alpha Chat Insight

“Theragen Etex Co., Ltd. trades at a P/E of 8.4 (undervalued) with solid ROE of 8.4%. 3Y revenue CAGR of 12.5% highlights clear growth momentum.”

Ask for details →

Company Overview

Theragen Etex Co., Ltd. is a prominent player in the healthcare and pharmaceutical industry. The company specializes in biopharmaceuticals, leveraging cutting-edge technology to pave the way for advancements in genetic research and personalized medicine. With a keen focus on genomics, Theragen Etex offers services in DNA analysis and sequencing, aiming to understand genetic data to improve diagnostic and therapeutic outcomes. Primarily catering to the healthcare sector, it also has a footprint in the area of dental materials, expanding its reach and impact. By concentrating its efforts on innovative healthcare solutions, Theragen Etex plays a pivotal role in addressing complex health challenges and contributing to the broader field of biotechnology. As the demand for personalized healthcare options continues to grow, the company's role in supplying precision medicine solutions positions it as a crucial entity in the evolving biopharmaceutical landscape.

CEO고진업, 박시홍

Websitehttps://www.theragenetex.com

SectorCommon Stock

IndustryCommon Stock

Company Statistics

FY 2025

Profile

₩89,537,226,160Market Cap

₩271,589,661,720Revenue

37.15MShares Out

0Employees

Margins

51.92%Gross

6.23%EBITDA

3.76%Operating

6.46%Pre-Tax

4.32%Net

Valuation

8.45P/E

0.64P/B

0.33EV/Sales

6.85EV/EBITDA

15.50P/FCF

Growth (CAGR)

12.50%Rev 3Yr

13.68%Rev 5Yr

-4.93%Op Inc 3Yr

N/AOp Inc 5Yr

2.36%Net Inc 3Yr

N/ANet Inc 5Yr

Returns

4.75%ROA

8.44%ROE

8.03%ROIC

Financial Health

₩35,354,921,760Cash & Cash Equivalents

₩63,103,272,420Net Debt

61.86%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Theragen Etex Co., Ltd. trades at a P/E of 8.4 (undervalued) with solid ROE of 8.4%. 3Y revenue CAGR of 12.5% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Theragen Etex Co., Ltd. (ticker: 066700) is a company listed on KRX in the Common Stock sector (Common Stock). Market cap is $89.5B.

The current price is ₩2,410 with a P/E ratio of 8.45x and P/B of 0.64x.

ROE is 8.44% and operating margin is 3.76%. Annual revenue is $271.6B.